whole-genome sequencing
GeneDx Stock Soars as Firm Reports 44 Percent Revenue Growth, $1.2M Adjusted Net Income in Q3
Premium
Revenues in the third quarter were driven by diagnostic exome and genome tests, which grew 76 percent in revenue and 46 percent in volume, prompting the firm to raise its 2024 guidance.
Variantyx Combines Long Nanopore, Short Illumina Reads for Rare Disease Whole-Genome Diagnostic Test
Premium
The firm recently launched the Genomic Unity 2.0 assay, which it claims is the first commercial diagnostic rare disease test to include nanopore sequencing.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
Craig-Hallum Initiates Coverage of GeneDx With Buy Rating
The investment bank cited the firm's strong growth in its whole-exome and whole-genome sequencing businesses and a clear path to profitability.
GMS will also use the funding for studies related to childhood cancer and rare diseases and to continue the development of a National Genomics Platform.